Janney Montgomery Scott LLC Sells 766 Shares of IDEXX Laboratories, Inc. (IDXX)

Janney Montgomery Scott LLC lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.2% during the first quarter, Holdings Channel reports. The institutional investor owned 4,612 shares of the company’s stock after selling 766 shares during the period. Janney Montgomery Scott LLC’s holdings in IDEXX Laboratories were worth $1,031,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IDXX. JPMorgan Chase & Co. raised its stake in shares of IDEXX Laboratories by 12.4% during the third quarter. JPMorgan Chase & Co. now owns 379,302 shares of the company’s stock valued at $94,697,000 after acquiring an additional 41,716 shares during the last quarter. Morgan Stanley raised its stake in shares of IDEXX Laboratories by 15.1% during the third quarter. Morgan Stanley now owns 439,913 shares of the company’s stock valued at $109,830,000 after acquiring an additional 57,828 shares during the last quarter. Vanguard Group Inc raised its stake in shares of IDEXX Laboratories by 0.3% during the third quarter. Vanguard Group Inc now owns 8,918,451 shares of the company’s stock valued at $2,226,581,000 after acquiring an additional 23,970 shares during the last quarter. DNB Asset Management AS raised its stake in shares of IDEXX Laboratories by 9.9% during the fourth quarter. DNB Asset Management AS now owns 18,811 shares of the company’s stock valued at $3,499,000 after acquiring an additional 1,700 shares during the last quarter. Finally, Lavaca Capital LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at $230,000. Hedge funds and other institutional investors own 87.46% of the company’s stock.

In related news, VP Jacqueline Studer sold 2,529 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $210.57, for a total transaction of $532,531.53. Following the completion of the transaction, the vice president now owns 6,918 shares of the company’s stock, valued at $1,456,723.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Michael Lane sold 736 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 20th. The stock was sold at an average price of $211.58, for a total transaction of $155,722.88. Following the transaction, the vice president now directly owns 6,468 shares of the company’s stock, valued at approximately $1,368,499.44. The disclosure for this sale can be found here. Insiders have sold 52,886 shares of company stock valued at $12,910,319 in the last three months. 2.70% of the stock is owned by insiders.

IDXX has been the subject of several analyst reports. Canaccord Genuity raised their price target on shares of IDEXX Laboratories from $255.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. BidaskClub raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, March 22nd. Finally, Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 price target for the company in a research note on Monday, February 4th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. IDEXX Laboratories currently has an average rating of “Buy” and an average price target of $253.50.

Shares of NASDAQ IDXX opened at $249.56 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $176.11 and a twelve month high of $256.22. The firm has a market cap of $21.47 billion, a P/E ratio of 58.58 and a beta of 0.97. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $1.04 by $0.13. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. The business had revenue of $576.06 million during the quarter, compared to the consensus estimate of $575.04 million. During the same quarter last year, the firm earned $1.01 earnings per share. IDEXX Laboratories’s quarterly revenue was up 7.1% on a year-over-year basis. On average, research analysts predict that IDEXX Laboratories, Inc. will post 4.82 EPS for the current fiscal year.

WARNING: “Janney Montgomery Scott LLC Sells 766 Shares of IDEXX Laboratories, Inc. (IDXX)” was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/19/janney-montgomery-scott-llc-sells-766-shares-of-idexx-laboratories-inc-idxx.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.